Radiolabeled prostate specific membrane antigen inhibitors
View Patent ↗Compounds according to Formula I and Formula II are potent inhibitors of PSMA activity: The invention also provides pharmaceutical compositions of a complex of a radionuclide and a Formula I compound or a Formula II compound and methods of using the radionuclide complex of a Formula I compound or a Formula II compound for treating or diagnosis of a disease or a condition associated with PSMA activity.
1. A compound represented by formula II
wherein:
X and Y are each independently (CHR 1 ) m or C(O);
W is H, ═O—(CHR 1 ) m —(CH 2 ) p —, or —(CH 2 ) p —U;
represents a single or a double bond;
L is —C(O)—(C 1 -C 10 )alkylene, —[C(O)—(CH(Z) d )—NH]; NR 2 R 3 , —C(O)—(CHR 1 )—(CH 2 ) p —U—, —(C 5 -C 14 )aryl-(C 1 -C 10 )alkylene, R 7 -benzyl, —(C 5 -C 14 )heteroaryl-(C 1 -C 10 )alkylene, —C(O)—[(CH 2 ) p —V] n —(CH 2 ) q —C(O)—U, [C(O)—CH(Z) d —NH] t —C(O)—(CHR 1 ) m —(CH 2 ) p —[U] r , —C(S)—NH-benzylene, —C(O)—NH-benzylene, —[C(O)—(CH(Z) d )—NH] s -benzylene-, or —(C 1 -C 10 )alkylene-NR 4 R 5 ;
T is selected from the group consisting of: H, —(C 1 -C 10 )alkylene, RC(O)—(C 1 -C 10 )alkylene, NR 2 R 3 —(C 1 -C 10 )alkylene, —(C 5 -C 14 )heteroaryl-(C 1 -C 10 )alkylene, —(C 5 -C 14 )aryl-(C 1 -C 10 )alkylene and R 6 —(C 5 -C 14 )heteroarylene-(C 1 -C 10 )alkylene;
U is selected from the group consisting of: —OR, —COR, —(C 5 -C 14 )arylene and —NR 4 R);
V is selected from the group consisting of: —NH—, —NR 2 — and —NR 2 R 3 ;
Z is —(CH 2 ) p —COOH, —(CH 2 ) p —(C 5 -C 14 )aryl, or —(CH 2 ) p —NR 2 R 3 ;
R, R a and R b are each independently —H, —OH, —(C 1 -C 10 )alkyl, —O(C 1 -C 10 )alkyl, —NHR 2 , or —NR 2 R 3 ;
R 1 and R′″ are each independently —H, —NH 2 , or —(CH 2 ) p —U;
R 2 , R 3 , R 4 , R 5 and R 6 are each independently H, bond, (C 1 -C 10 )alkylene, F, Cl, Br, I, C(O), C(S), —C(S)—NH-benzyl-, —C(O)—NH-benzyl-, —C(O)—(C 1 -C 10 )alkylene, —(CH 2 ) v —NR 4 , —(CH 2 ) p —NH—C(O)—(CH 2 ) p —, —(CH 2 —CH 2 ) t —NH—C(O)—(CH 2 ) p —, —(CH 2 ) p —COR, —(CH 2 ) p —C(O)NH—C[(CH 2 ) p —COR] 3 , —C[(CH 2 ) p —COR] 3 , or —(CH 2 ) p —(C 5 -C 14 )heteroaryl;
R 7 is —O(CH 2 ) p —(C 5 -C 14 )heteroaryl-(CH 2 ) p —U;
D is
and
d, j, k, m, n, p, q, r, s, t and v are each independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
with the proviso that where W is —(CH 2 ) 5 — or —CH(NH 2 )—(CH 2 ) 4 —, then L is not —C(O)CH 2 —.
2. The compound of claim 1 , which is:
3. A metal complex comprising a radionuclide and the compound of claim 1 .
4. The metal complex of claim 3 , wherein the radionuclide is 111 In, 90 Y, 68 Ga, 64 Cu 153 Gd, 155 Gd, 157 Gd, Fe or 177 Lu.
5. The metal complex of claim 3 , which is:
or a pharmaceutically acceptable salt thereof;
wherein M is 111 In, 90 Y, 68 Ga, 64 Cu, or 177 Lu.
6. The compound of claim 1 , wherein any aryl, arylalkylene, benzyl, heteroaryl, or cycloalkyl group is substituted with 1, 2, or 3 substituent groups selected from the group consisting of: —(C 1 -C 10 )alkyl, halogen, —(C 1 -C 10 )haloalkyl, —(C 1 -C 10 )aminoalkyl, —(C 1 -C 10 )hydroxyalkyl, —(CH 2 ) p —C(O)—U and —(C 3 -C 8 )cycloalkyl.
7. A pharmaceutical composition comprising the compound of claim 1 or the metal complex of claim 5 , or a pharmaceutically acceptable salt, solvate, or ester thereof; and a pharmaceutically acceptable carrier.